MDA 2021 poster: Steroid switching in the treatment of dystrophinopathies in the US: A nationwide chart review of patient characteristics and clinical outcomes
This poster, displayed at the 2021 virtual MDA Conference, shows findings from an investigation into the real-world reasons for switching between corticosteroids for the treatment of dystrophinopathies
Explore the results from a chart review of 102 patients with either Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD)
Review the clinical decisions for switching corticosteroid treatment from prednisolone/prednisone to deflazacort
Understand the reasons for switching, including desire to improve benefit/risk outcome, tolerability issues, and requests from the patient/caregiver
Deflazacort is a corticosteroid indicated for the treatment of DMD in patients 2 years of age and older. PTC Therapeutics is the Marketing Authorization Holder for deflazacort in the US only. Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The US Prescribing Information for deflazacort is available here. Please refer to your local country guidance for more information.